Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also involved in the development of CS23546, a small molecule PD-L1 inhibitor, which relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway; CS231295, a brain-penetrating selective Aurora B inhibitor; and CS32582, a small-molecule allosteric inhibitor of tyrosine kinase 2. In addition, the company develops CS08399, a potential brain-penetrating PRMT5-MTA inhibitor for BIC; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Research context
Shenzhen Chipscreen Biosciences Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shenzhen Chipscreen Biosciences Co., Ltd is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
From a valuation standpoint, the stock is 499.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 57.7.
Shenzhen Chipscreen Biosciences Co., Ltd's total revenue rose by 84.5% to $83M since the same quarter in the previous year.
Its net income has dropped by 424.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 146.4% to $-97M since the same quarter in the previous year.
Based on the above factors, Shenzhen Chipscreen Biosciences Co., Ltd gets an overall score of 2/5.